Inventor · disambiguated record
Ezio Bonvini
Also filed as: BONVINI EZIO
41 granted patents·33 pending applications·528 citations·filing 2005–2025
98Inventor score
Top patents by PatentIndex Score
74 records- 0198US8946387B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Feb 3, 2015·82 cites·25 claims
- 0298US8193318B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Jun 5, 2012·77 cites·6 claims
- 0397US9822181B2Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereofMACROGENICS INC·Filed 2014·Granted Nov 21, 2017·62 cites·32 claims
- 0496US10131713B2HER2/neu-specific antibodies and methods of using sameMACROGENICS INC·Filed 2016·Granted Nov 20, 2018·10 cites·20 claims
- 0596US8802093B2HER2/neu-specific antibodies and methods of using sameJOHNSON LESLIE S·Filed 2009·Granted Aug 12, 2014·33 cites·15 claims
- 0696US8187593B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted May 29, 2012·63 cites·15 claims
- 0795US11623959B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2020·Granted Apr 11, 2023·6 cites·23 claims
- 0895US10633440B2Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2015·Granted Apr 28, 2020·11 cites·18 claims
- 0995US10577422B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 3, 2020·19 cites·10 claims
- 1095US10160806B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2015·Granted Dec 25, 2018·18 cites·34 claims
- 1195US9469692B2HER2/neu-specific antibodies and methods of using sameMACROGENICS INC·Filed 2016·Granted Oct 18, 2016·8 cites·14 claims
- 1294US10787521B2Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereofMACROGENICS INC·Filed 2017·Granted Sep 29, 2020·7 cites·18 claims
- 1394US10647768B2Multi-chain polypeptide-containing tri-specific binding moleculesMACROGENICS INC·Filed 2015·Granted May 12, 2020·19 cites·21 claims
- 1494US9243069B2HER2/neu-specific antibodies and methods of using the sameMACROGENICS INC·Filed 2014·Granted Jan 26, 2016·13 cites·9 claims
- 1593US11858991B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2021·Granted Jan 2, 2024·2 cites·18 claims
- 1691US11028183B2HER2/neu-specific antibodies and methods of using sameMACROGENICS INC·Filed 2018·Granted Jun 8, 2021·3 cites·38 claims
- 1791US8663634B2Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicityKOENIG SCOTT·Filed 2006·Granted Mar 4, 2014·25 cites·12 claims
- 1889US11685781B2Variant CD3-binding domains and their use in combination therapies for the treatment of diseaseMACROGENICS INC·Filed 2019·Granted Jun 27, 2023·4 cites·33 claims
- 1989US11459394B2Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2018·Granted Oct 4, 2022·4 cites·8 claims
- 2089US11384149B2Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereofMACROGENICS INC·Filed 2019·Granted Jul 12, 2022·4 cites·13 claims
- 2188US11072653B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Jul 27, 2021·4 cites·17 claims
- 2288US10954301B2Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 23, 2021·3 cites·8 claims
- 2388US9056906B2Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicityKOENIG SCOTT·Filed 2007·Granted Jun 16, 2015·12 cites·8 claims
- 2487US11942149B2Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2022·Granted Mar 26, 2024·1 cites·14 claims
- 2586US11098119B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2018·Granted Aug 24, 2021·2 cites·14 claims
- 2686US11078279B2Combination therapy for the treatment of cancerMACROGENICS INC·Filed 2016·Granted Aug 3, 2021·5 cites·20 claims
- 2786US10633443B2Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereofMACROGENICS INC·Filed 2015·Granted Apr 28, 2020·3 cites·9 claims
- 2886US9376495B2Deimmunized serum-binding domains and their use in extending serum half-lifeBONVINI EZIO·Filed 2012·Granted Jun 28, 2016·13 cites·26 claims
- 2985US2024117036A1Tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2023·Application pending·0 cites
- 3085US2024182559A1MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENSMACROGENICS INC·Filed 2023·Application pending·0 cites
- 3184US11697684B2Tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2020·Granted Jul 11, 2023·1 cites·13 claims
- 3284US11639386B2Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereofMACROGENICS INC·Filed 2020·Granted May 2, 2023·1 cites·10 claims
- 3384US2025304685A1Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereofMACROGENICS INC·Filed 2025·Application pending·0 cites
- 3484US2025313628A1Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereofMACROGENICS INC·Filed 2025·Application pending·0 cites
- 3583US11820818B2Multi-chain polypeptide-containing tri-specific binding moleculesMACROGENICS INC·Filed 2020·Granted Nov 21, 2023·1 cites·16 claims
- 3683US11242402B2ADAM9-binding molecules, and methods of use thereofMACROGENICS INC·Filed 2017·Granted Feb 8, 2022·2 cites·38 claims
- 3781US10344092B2Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereofMACROGENICS INC·Filed 2014·Granted Jul 9, 2019·5 cites·9 claims
- 3881US2023399399A1Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses ThereofMACROGENICS INC·Filed 2023·Application pending·0 cites
- 3980US2025115676A1ADAM9-Binding Molecules, and Methods of Use ThereofMACROGENICS INC·Filed 2024·Application pending·0 cites
- 4080US2024084015A1Methods of using bispecific molecules having immunoreactivity with pd-1 and ctla-4MACROGENICS INC·Filed 2023·Application pending·0 cites
- 4179US11174315B2Combination therapy for the treatment of cancerMACROGENICS INC·Filed 2016·Granted Nov 16, 2021·2 cites·39 claims
- 4278US12024569B2HER2/neu-specific antibodies and methods of using sameMACROGENICS INC·Filed 2021·Granted Jul 2, 2024·0 cites·21 claims
- 4378US10961311B2B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereofMACROGENICS INC·Filed 2017·Granted Mar 30, 2021·1 cites·39 claims
- 4476US9932400B2Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereofMACROGENICS INC·Filed 2014·Granted Apr 3, 2018·2 cites·20 claims
- 4574US2022041714A1Covalently Bonded Diabodies Having Immunoreactivity with PD-1 and LAG-3, and Methods of Use ThereofMACROGENICS INC·Filed 2021·Application pending·0 cites
- 4673US11840571B2Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4MACROGENICS INC·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 4773US2023272084A1B7-h3 directed antibody drug conjugatesMACROGENICS INC·Filed 2023·Application pending·0 cites
- 4872US2024043537A1Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of DiseaseMACROGENICS INC·Filed 2023·Application pending·0 cites
- 4971US2024233818A1Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2024·Application pending·0 cites
- 5070US2022324995A1ADAM9-Binding Molecules, and Methods of Use ThereofMACROGENICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ezio Bonvini files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →